Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Oncobiologics Inc. Stories

2013-08-06 12:26:34

CRANBURY, N.J., Aug. 6, 2013 /PRNewswire/ -- Oncobiologics, Inc. and inVentiv Health today announced a broad strategic partnership around clinical development for all assets in Oncobiologic's pipeline. The scope of the partnership is global and will initially focus on biosimilar assets, and could be expanded to include innovative molecules. Through the partnership, inVentiv Health will provide leadership and execution for clinical studies, as well as the corresponding...

2013-05-08 08:31:37

CRANBURY, N.J., May 8, 2013 /PRNewswire/ -- Oncobiologics, Inc. announced today that Zhejiang Huahai Pharmaceutical Co., Ltd and Oncobiologics have signed an alliance agreement for the development, manufacture and commercialization of biosimilar monoclonal antibody products. The scope of the agreement includes exclusive commercialization by Huahai of four biosimilars developed by Oncobiologics and manufactured in China at a Huahai biologics facility for the China market, and will also...

2012-11-06 08:29:00

CRANBURY, N.J. and CAMBRIDGE, Mass., Nov. 6, 2012 /PRNewswire/ -- Oncobiologics, Inc. and Boston Oncology, LLC today announced a strategic partnership that will allow Boston Oncology to license, manufacture, and commercialize four of Oncobiologics' biosimilar therapies for cancer and immunological disease in the Middle East and North African (MENA) regions. Under the agreement, Boston Oncology--a pharmaceutical company that localizes advanced technologies and manufacturing expertise in the...

2012-07-30 06:25:20

CRANBURY, N.J., July 30, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today a collaboration agreement with XOMA Corporation to develop novel biotherapeutics based on engineering single-chain variable fragments (scFv) into a bi-specific antibody scaffold. Through the partnership, Oncobiologics will utilize XOMA's ADAPT(TM) fully human antibody technology platform as a key component of its drug discovery program. Oncobiologics has selected clinically validated targets that will be used in...

2012-05-25 02:21:23

CRANBURY, N.J., May 25, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today that it has filled two important leadership positions with established biopharmaceutical industry experts. Stephen J. McAndrew, Ph.D. is now Vice President, Business Development and Vincent J. Benn, Ph.D. has joined the company as Vice President, Clinical & Regulatory Affairs. The company also announced its new Scientific Advisory Board, which will be headed by Joseph Bertino, M.D., currently Chief Scientific...

2011-10-17 09:00:00

CRANBURY, N.J., Oct. 17, 2011 /PRNewswire/ -- Sen. Robert Menendez (D-NJ), Lt. Gov. Kim Guadagno and regional leaders of the biopharmaceutical industry Friday unveiled the state-of-the-art home of Oncobiologics, a novel biotech firm enabled, in part, by the U.S. Affordable Care Act. (Photo: http://photos.prnewswire.com/prnh/20111017/PH87451 ) "We are committed to advancing innovative and improved biotherapeutics to treat serious diseases, including cancer and immune disorders, by...

2011-10-13 09:00:00

CRANBURY, N.J., Oct. 13, 2011 /PRNewswire/ -- Oncobiologics announced today that it has signed two major agreements. The first is with Parilis Biopharmaceuticals, an early-stage biotech company, and involves worldwide licensing for an undisclosed biotherapeutic product. The second is with a US based large pharmaceutical company to conduct research focused on solving issues related to downstream processing of monoclonal antibodies. The identity of the client firm was not disclosed due to...

2011-10-12 09:31:00

CRANBURY, N.J., Oct. 12, 2011 /PRNewswire/ -- Oncobiologics, Inc. announced today that is has named Scott Canute, a former President at both Eli Lilly and Genzyme, to its Board of Directors. Over the course of his 30-year career, Mr. Canute played a vital role in leading Eli Lilly's global manufacturing operations. Most recently, he spent more than a year as President of Global Manufacturing and Corporate Operations for Genzyme, where he led a major turnaround effort. "Scott Canute has...

2011-08-22 11:06:00

CRANBURY, N.J. and PHILADELPHIA, Aug. 22, 2011 /PRNewswire/ -- Oncobiologics, Inc. and Fox Chase Cancer Center announced today an agreement to co-develop a novel, next generation bi-specific antibody cancer platform with enhanced therapeutic capabilities against solid tumors. The jointly engineered platform is designed to handle multiple targets, representing a pipeline of promising cancer treatments. This research program is now underway, with preclinical studies expected in Q1-2012 for...

2011-06-21 07:07:00

CRANBURY, N.J., June 21, 2011 /PRNewswire/ -- The founders of Oncobiologics, Inc. today announced that the firm, a specialist in biologics proof-of-concept services, will launch itself to the biopharmaceutical industry at the 2011 BIO International Convention. The convention is being held June 27-30 at the Walter E. Washington Convention Center in Washington, DC (booth 1950). Oncobiologics was founded by a group of leading scientists and engineers from top-tier global pharmaceutical and...